Recently, Blood published the results of a retrospective study on the outcomes of different salvage treatments (≥ one line) in 79 MM patients with progression after anti-BCMA CAR-T therapy [120]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.